Abbott Laboratories, Meet Estimates
For the full calendar of 2024, Abbott recorded sales of $41.95 billion, following the launches last year of a new heart valve ...
Abbott reported fourth-quarter results that missed the consensus sales forecast — but medical device sales remain a bright ...
Abbott's Q4 sales grow 7.2%, missing estimates, but analysts remain upbeat with strong 2025 projections driven by Diabetes ...
Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target of ...
The company’s projected adjusted diluted EPS for 2025 is between $5.05 and $5.25, marking double-digit growth at the midpoint. Abbott’s first-quarter 2025 adjusted EPS is expected to be between $1.05 ...
Abbott's Q4 sales reached $10.97 billion, with 8.8% organic growth. EPS met expectations at $1.34, driven by strong ...
Analyst Lee Hambright of Bernstein maintained a Buy rating on Abbott Laboratories (ABT – Research Report), boosting the price target to ...
Abbott (NYSE:ABT) today highlighted significant growth within its Diabetes business amid its fourth-quarter results for 2024.
For 2025, Abbott forecast organic sales growth of between 7.5% and 8.5%, as well as adjusted earnings per share of $5.05 to $5.25. Analysts expect $5.16 a share on $42 billion in sales.
Cardiac device innovations made waves in 2024, with regulatory approvals, clinical breakthroughs, and product launches ...
(Reuters) - Abbott Laboratories on Wednesday forecast 2025 profit that came in line with Wall Street estimates as it expects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback